Clinical Trials
4 trialsNCT06441747 2026-05-06
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT03297606 2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03838744 2024-12-04
TOMAS2
Italian Sarcoma Group
Phase 2 Completed
NCT05209529 2024-02-23
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn